DSpace at RU >

Search Results

Results 1-19 of 19.

Item hits:

Full Text	Issue Date	Title	Author(s)
	2011	A Sezary cryptogram. Disseminated cryptococcal infection	Desar, I.M.E.; Stevens, W.B.C.; Verweij, P.E.; Velden, W.J.F.M. van der
	2011	A new, simple and objective prognostic score for phase I cancer patients	Fussenich, L.M.; Desar, I.M.E.; Peters, M.E.W.J.; Teerenstra, S.; Graaf, W.T. van der; Timmer-Bonte, J.N.H.; Herpen, C.M. van
	2011	A phase I study of recombinant human interleukin-21 (rIL-21) in combination with sunitinib in patients with metastatic renal cell carcinoma (RCC)	Grunwald, V.; Desar, I.M.E.; Haanen, J.; Fiedler, W.; Mouritzen, U.; Olsen, M.W.; Herpen, C.M. van
	2011	Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients	Desar, I.M.E.; van Herpen, C.M.; van Asten, J.J.; Fiedler, W.; Marreaud, S.; Timmer-Bonte, J.N.H.; Voert, E.G.W. ter; Lambiase, A.; Bordignon, C.; Heerschap, A.; Laarhoven, H.W.M. van
	2011	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients	Desar, I.M.E.; Jacobs, J.F.M.; Hulsbergen- van de Kaa, C.A.; Oyen, W.J.G.; Mulders, P.F.A.; van der Graaf, W.T.; Adema, G.J.; van Herpen, C.M.; Vries, I.J.M. de
	2011	Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination	Mulder, S.F.; Jacobs, J.F.M.; Olde Nordkamp, M.A.M.; Galama, J.M.D.; Desar, I.M.E.; Torensma, R.; Teerenstra, S.; Mulders, P.F.; Vissers, K.C.P.; Punt, C.J.A.; Vries, I.J.M. de; Herpen, C.M.L. van
	2010	Advanced monitoring of targeted therapy in cancer	Desar, I.M.E.
	2010	A patient with renal cell carcinoma and thoracic pain.	Desar, I.M.E.; Sonderen, M.J.; Herpen, C.M.L. van
	2010	Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.	Desar, I.M.E.; Bovenschen, H.J.; Timmer-Bonte, J.N.H.; Cantarini, M.V.; Graaf, W.T.A. van der; Rossum, M.M. van; Herpen, C.M.L. van
	2010	A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.	Desar, I.M.E.; Timmer-Bonte, J.N.H.; Burger, D.M.; Graaf, W.T.A. van der; Herpen, C.M.L. van
	2010	A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.	Herpen, C.M.L. van; Eskens, F.A.; Jonge, M. de; Desar, I.M.E.; Hooftman, L.; Bone, E.A.; Timmer-Bonte, J.N.H.; Verweij, J.
	2010	The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer.	Banerji, U.; Camidge, D.R.; Verheul, H.M.; Agarwal, R.; Sarker, D.; Kaye, S.B.; Desar, I.M.E.; Timmer-Bonte, J.N.H.; Eckhardt, S.G.; Lewis, K.D.; Brown, K.H.; Cantarini, M.V.; Morris, C.; George, S.M.; Smith, P.D.; Herpen, C.M.L. van
	2010	111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.	Desar, I.M.E.; Stillebroer, A.B.; Oosterwijk, E.; Leenders, W.P.J.; Herpen, C.M.L. van; Graaf, W.T.A. van der; Boerman, O.C.; Mulders, P.F.A.; Oyen, W.J.G.
	2010	Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).	Laarhoven, H.W.M. van; Fiedler, W.; Desar, I.M.E.; Asten, J.J.A. van; Marreaud, S.; Lacombe, D.; Govaerts, A.S.; Bogaerts, J.; Lasch, P.; Timmer-Bonte, J.N.H.; Lambiase, A.; Bordignon, C.; Punt, C.J.A.; Heerschap, A.; Herpen, C.M.L. van
	2009	The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.	Desar, I.M.E.; Mulder, S.F.; Stillebroer, A.B.; Spronsen, D.J. van; Graaf, W.T.A. van der; Mulders, P.F.A.; Herpen, C.M.L. van
	2009	Pharmacokinetics of sunitinib in an obese patient with a GIST.	Desar, I.M.E.; Burger, D.M.; Hoesel, Q.G.C.M. van; Beijnen, J.H.; Herpen, C.M.L. van; Graaf, W.T.A. van der
	2009	Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.	Desar, I.M.E.; Herpen, C.M.L. van; Laarhoven, H.W.M. van; Barentsz, J.O.; Oyen, W.J.G.; Graaf, W.T.A. van der
	2009	Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia.	Desar, I.M.E.; Deuren, M. van; Sprong, T.; Jansen, J.B.M.J.; Namavar, F.; Broucke-Grauls, C.M. van den; Meer, J.W.M. van der
	2008	Rapid and reliable identification of Streptococcus anginosus group isolates to the species level by real-time PCR and melting curve analysis.	Desar, I.M.E.; Boer, M. den; Bens, C.C.; Jacobs, J.A.; Mouton, J.W.; Dofferhoff, A.S.M.; Klaassen, C.H.W.

1